RecruitingLiver Cirrhosis
Coagulation in Cirrhosis
Eligible age
18+ yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Out of fear of bleeding, liver cirrhosis patients are often treated prophylactically with blood and coagulation products before minor interventions. The COUCH study will examine whether these patients benefit from a restrictive administration of coagulation products.
Sponsor: Medical University of Vienna
You may qualify if…
- ✓ Patients at the University Hospital of Vienna with diagnosed liver cirrhosis and deranged coagulation parameters (INR \>1,5 AND/ OR platelet count \<50 G/L) who are scheduled for one of the following elective invasive interventions of the liver
- ✓ Biopsy or puncture
- ✓ Microwave ablation (MWA) or radiofrequency ablation (RFA)
- ✓ Transjugular intrahepatic portosystemic shunt (TIPS)
- ✓ Percutaneous transhepatic cholangiography drain (PTCD)
You may not qualify if…
- ✕ Missing informed consent or inability to consent
- ✕ Age \< 18 years
- ✕ Pregnancy or breastfeeding
- ✕ Manifest ascites
- ✕ Chronic kidney injury stage G4 or G5, KDIGO
- ✕ Uninterrupted anticoagulant therapy, except for acetylsalicylic acid (ASA)
- ✕ History of bleeding or clinical signs of a hemorrhagic diathesis in the physical examination (e.g., petechia, ecchymosis, mucosal bleeding, hemorrhagic diathesis within the family, menorrhagia, prolonged bleeding after surgery)
Source: ClinicalTrials.gov · NCT05667805 · last updated 2025-01-14